353 related articles for article (PubMed ID: 38571944)
1. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM; Ho VT; Garcia JS
Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
6. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
[TBL] [Abstract][Full Text] [Related]
7. Chimerism, the Microenvironment and Control of Leukemia.
Deeg HJ
Front Immunol; 2021; 12():652105. PubMed ID: 33968052
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke J; Buka R; Craddock C
Front Immunol; 2021; 12():659595. PubMed ID: 34012445
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia.
Sterling C; Webster J
Am J Hematol; 2020 May; 95(5):529-547. PubMed ID: 32022292
[TBL] [Abstract][Full Text] [Related]
11. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y; Holtzman NG
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
Al-Shaibani E; Novitzky-Basso I; Mattsson J; Kim DDH
Int J Hematol; 2023 Jul; 118(1):1-17. PubMed ID: 37212948
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in allogeneic transplantation for acute myeloid leukemia.
Montoro J; Balaguer-Roselló A; Sanz J
Curr Opin Oncol; 2023 Nov; 35(6):564-573. PubMed ID: 37820092
[TBL] [Abstract][Full Text] [Related]
14. Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
Klyuchnikov E; Langebrake C; Badbaran A; Dadkhah A; Massoud R; Freiberger P; Ayuk F; Janson D; Wolschke C; Bacher U; Kröger N
Eur J Haematol; 2023 Feb; 110(2):188-197. PubMed ID: 36335432
[TBL] [Abstract][Full Text] [Related]
15. Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia.
Hilger N; Mueller C; Stahl L; Mueller AM; Zoennchen B; Dluczek S; Halbich C; Wickenhauser C; Gerloff D; Wurm AA; Behre G; Kretschmer A; Fricke S
Front Immunol; 2018; 9():2408. PubMed ID: 30405611
[TBL] [Abstract][Full Text] [Related]
16. New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia.
Mohty R; El Hamed R; Brissot E; Bazarbachi A; Mohty M
Haematologica; 2023 Feb; 108(2):321-341. PubMed ID: 36722403
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Lulla PD; Naik S; Vasileiou S; Tzannou I; Watanabe A; Kuvalekar M; Lulla S; Carrum G; Ramos CA; Kamble R; Hill L; Randhawa J; Gottschalk S; Krance R; Wang T; Wu M; Robertson C; Gee AP; Chung B; Grilley B; Brenner MK; Heslop HE; Vera JF; Leen AM
Blood; 2021 May; 137(19):2585-2597. PubMed ID: 33270816
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect.
Chandar R; Meena S; Varla H; Ramakrishnan B; Vellaichamy Swaminathan V; Uppuluri R; Raj R
Pediatr Transplant; 2022 Aug; 26(5):e14293. PubMed ID: 35437875
[TBL] [Abstract][Full Text] [Related]
19. How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia.
Velardi A; Mancusi A; Ruggeri L; Pierini A
Bone Marrow Transplant; 2024 Mar; 59(3):301-305. PubMed ID: 38212671
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
